JamesMarkClearyMD

PubMed

• RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
  Harshabad Singh, Pranshu Sahgal, Kevin Kapner, Steven M Corsello, Hersh Gupta, Rahul Gujrathi, Yvonne Y Li, Andrew D Cherniack, Raquelle El Alam, Joseph Kerfoot, Eliza...> ;Clinical Cancer Research. 2024 Apr 15
• Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer.
  Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards, Yingyun Wang, Bianca Lee, Margo Orlen, Sha Tian, Clint A Stalnecker, Kristina D...> ;Nature. 2024 Apr 8
• Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
  Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, Zsofia Sztupinszki, Clare X Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada L...> ;NPJ Precision Oncology. 2024 Apr 8
• FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
  Lixia Xu, Ying Zhang, Zhilong Lin, Xinlang Deng, Xiaoxue Ren, Mingle Huang, Shangru Li, Qianying Zhou, Fei Fang, Qingxia Yang, Gaomin Zheng, Zebin Chen, Zhongdao Wu, X...> ;Journal of Hepatology. 2024 Mar 18
• Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.
  Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
• First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 ...
  Janjigian, Y., Ajani, J., Moehler, M., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., Cleary, J., Elimova, E., Karamouzis, M., Bruges, R., Skoczylas,...> ;Journal of Clinical Oncology. 2024 Feb 21
• The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboringgene fusions.
  Kim, D., Schram, A., Hollebecque, A., Nishino, K., Macarulla, T., Rha, S., Duruisseaux, M., Liu, S., Al Hallak, M., Umemoto, K., Wesseler, C., Cleary, J., Springfeld, ...> ;Future Oncology. 2024 Feb 13
• Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
  Huffman, B., Singh, H., Ali, L., Horick, N., Wang, S., Hoffman, M., Metayer, K., Murray, S., Bird, A., Abrams, T., Biller, L., Chan, J., Meyerhardt, J., McCleary, N., ...> ;Journal for Immunotherapy of Cancer. 2024 Jan 25
• Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarci...
  Loriot, Y., Burgoyne, A., Santoro, A., Aix, S., Sudhagoni, R., Guo, X., Andrianova, S., Paulson, S., Li, D., Cleary, J., Lin, D., Garrido-Laguna, I.> ;Eclinicalmedicine. 2024 Jan 1
• NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
  Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward Kim, Stacey Stein, ...> ;British Journal of Cancer. 2024 Feb 1
• 1 citations
  A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Ad...
  Huffman, B., Feng, H., Parmar, K., Wang, J., Kapner, K., Kochupurakkal, B., Martignetti, D., Sadatrezaei, G., Abrams, T., Biller, L., Giannakis, M., Ng, K., Patel, A.,...> ;Clinical Cancer Research. 2023 Dec 15
• Retraction Note: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.
  Jadhav, H., Pantelidou, C., Phan, T., Grochala, C., Mehta, A., Guerriero, J., D'Andrea, A., Patterson-Fortin, J., Wulf, G., Wolpin, B., Stanger, B., Aguirre, A., Clear...> ;Nature Communications. 2023 Dec 11
• 1 citations
  Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.
  Pranshu Sahgal, Deepa T Patil, Pratyusha Bala, Zsofia M Sztupinszki, Viktoria Tisza, Sandor Spisak, Anna G Luong, Brandon Huffman, Aurel Prosz, Harshabad Singh, Jean-B...> ;Iscience. 2023 Nov 17
• Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline.
  Cecilia A Larocca, Christopher J Fay, Jesse P Hirner, Jeffrey A Meyerhardt, James M Cleary, Anna K Dewan, Nicole R LeBoeuf> ;JAMA Dermatology. 2023 Oct 1
• 3 citations
  Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
  Harshabad Singh, Rachel B Keller, Kevin S Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan, Elizabeth F Cohen, Michael Tolstorukov, Elizabeth Andrews, Lauren K Brai...> ;Clinical Cancer Research. 2023 Nov 14
• Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.
  Harshabad Singh, Samuel J Klempner, Nelya Melnitchouk, Deepak P Chander, Ovidiu George Negrea, Anuj K Patel, Benjamin L Schlechter, Douglas A Rubinson, Brandon M Huffm...> ;JCO Precision Oncology. 2023 Jun 1
• G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
  Victoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, S Jennifer Wang, Lauren K Brais, Joshua Remland, C Elizabeth Keheler, Keri M Sullivan, Thomas A Abrams, Leah...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
• 7 citations
  SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach.
  Alexander J Neil, Lei Zhao, Raymond A Isidro, Amitabh Srivastava, James M Cleary, Fei Dong> ;Modern Pathology. 2023 Jun 1
• 1 citations
  USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
  Naiara Perurena, Rebecca Lock, Rachel A Davis, Srivatsan Raghavan, Natalie F Pilla, Raymond Ng, Patrick Loi, Caroline J Guild, Abigail L Miller, Ewa Sicinska, James M ...> ;Cell Reports. Medicine. 2023 Apr 18
• 1 citations
  Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.
  Pranshu Sahgal, Deepa T Patil, Zsofia M Sztupinszki, Viktoria Tisza, Sandor Spisak, Brandon Huffman, Aurel Prosz, Harshabad Singh, Jean-Bernard Lazaro, Zoltan Szallasi...> ;Biorxiv. 2023 Mar 28
• 1 citations
  Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
  Richard Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry Miao, Haig Inguilizian, James M Cl...> ;Cancer Chemotherapy and Pharmacology. 2023 Apr 1
• A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic can...
  Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tian...> ;Future Oncology. 2023 Apr 1
• 10 citations
  Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.
  Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K Mehta, Jennifer L Guerriero, Gerburg M Wulf, Brian M Wolpin, Ben Z Sta...> ;Nature Communications. 2023 Mar 13
• 3 citations
  Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
  Kimberly Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffr...> ;The Oncologist. 2023 May 8
• 10 citations
  Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
  James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
• Join now to see all